Business
Key Moditope paper published in Cancer Research
Key Moditope paper published in Cancer Research.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 7930K Scancell Holdings Plc 05 January 2016 \n\n05 January 2016\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nKey Moditope® paper published in Cancer Research\n \nModitope® citrullinated peptides stimulate potent anti-tumour responses \n \n \nScancell Holdings Plc, (AIM:SCLP), today announced the publication, on line, of a full paper in Cancer Research describing the rationale behind the Company's ModitopeÒ platform and the experimental results that support it.1 Cancer Research is the official journal of the American Association for Cancer Research and is one of the world's foremost peer-reviewed journals in the field of oncology.\n \nProf Lindy Durrant, Joint CEO of Scancell, said: \"The publication of this paper on the science behind Moditope® in such a prestigious and widely read cancer journal is not only a great achievement for the research team at Scancell, it provides a ringing endorsement from the scientific community for this completely innovative approach to the treatment of cancer. This important paper lays out the foundation, rationale and experimental basis for the Moditope® platform and its potential to generate effective cancer vaccines.\"\n \nThe lead product from the Moditope® platform, Modi-1, is progressing through pre-clinical development with first in man studies targeted in triple negative breast cancer and ovarian cancer patients. \n \nAbstract\n \nCitrullinated vimentin presented on MHC-II in tumor cells is a target for CD4+ T cell-mediated antitumor immunity\n \n\"Stressful conditions in the harsh tumor microenvironment induce autophagy in cancer cells as a mechanism to promote their survival. However, autophagy also causes post-translational modification of proteins which are recognized by the immune system. In particular, modified self-antigens can trigger CD4+ T cell responses that might be exploited to boost antitumor immune defenses. In this study, we investigated the ability of CD4 cells to target tumor-specific self-antigens modified by citrullination, which converts arginine residues in proteins to citrulline. Focusing on the intermediate filament protein vimentin, which is frequently citrullinated in cells during epithelial-to-mesenchymal transition of metastasizing epithelial tumors, we...